Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2016

View Archived Issues

FDA grants orphan drug designation for ATI-1501

Noveome debuts with topline data from phase I trials of ST-266

Karos Pharmaceuticals advances KAR-5585 into clinical development

Replikins tests trivalent Zika-Dengue-Japanese encephalitis vaccine candidate

Parker Institute for Cancer Immunotherapy established with USD 250 million grant

Phase I/II trial of TG-01 shows immune response with reduced number of vaccinations

European grant supports Orgenesis' work in type 1 diabetes

Lead Discovery Center and Merck KGaA disclose LMP7 inhibitors

Genentech and Roche describe BTK inhibitors

Korea Institute of Science and Technology patents MAO-B inhibitors

McGill University reports AR ligands

Riboscience divulges respiratory syncytial virus RNA replication inhibitors

Researchers present results from in vitro and in vivo studies of WCK-4282

QIAGEN and Mirati partner on companion diagnostic test for use with glesatinib

SIGA Technologies emerges from chapter 11 bankruptcy following court approval

Mul-1867 shows promising activity against multidrug-resistant Pseudomonas aeruginosa

Evaluating safety and pharmacokinetics in dose escalation of WCK-771 and WCK-2349

Intrexon establishes collaborations with startups backed by Harvest Intrexon Enterprise Fund

PDS Biotechnology completes phase I study for PDS-0101

Novel regulatory mutations may be associated with OTCD

FDA accepts sBLA and grants priority review for Keytruda in head and neck cancer

Vernalis completes CCP-08 bioavailability study

DNDi and Pharco Pharmaceuticals to test ravidasvir and sofosbuvir as affordable hepatitis C regimen

Wallenberg Foundation grants support work at Karolinska Institutet

New data from OpT2mise study support use of Medtronic's insulin pumps for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...